Abstract
Current interferon-free regimens are highly effective in the treatment of hepatitis C virus (HCV) genotype 1 infection, but other HCV genotypes still require treatment with ribavirin, which can cause problematic cases of anemia, pruritus, and insomnia in certain patients. In an ongoing industry-funded phase IIb study of a once-daily combination pill of ombitasvir, …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
